Replicel Life Sciences Stock Net Income
| REPCF Stock | USD 0.0001 0.00 0.00% |
Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of RepliCel Life, as well as the relationship between them.
RepliCel Life's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing RepliCel Life's valuation are provided below:RepliCel Life Sciences does not presently have any trending fundamental ratios for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. RepliCel |
RepliCel Life 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to RepliCel Life's pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of RepliCel Life.
| 11/07/2025 |
| 02/05/2026 |
If you would invest 0.00 in RepliCel Life on November 7, 2025 and sell it all today you would earn a total of 0.00 from holding RepliCel Life Sciences or generate 0.0% return on investment in RepliCel Life over 90 days. RepliCel Life is related to or competes with Sigyn Therapeutics, Zelira Therapeutics, and Mosaic Immunoengineerin. RepliCel Life Sciences Inc., a regenerative medicine company, focuses on developing autologous cell therapies that treat... More
RepliCel Life Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure RepliCel Life's pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess RepliCel Life Sciences upside and downside potential and time the market with a certain degree of confidence.
RepliCel Life Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for RepliCel Life's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as RepliCel Life's standard deviation. In reality, there are many statistical measures that can use RepliCel Life historical prices to predict the future RepliCel Life's volatility.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of RepliCel Life's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
RepliCel Life Sciences Backtested Returns
We have found three technical indicators for RepliCel Life Sciences, which you can use to evaluate the volatility of the company. The company holds a Beta of 0.0, which implies not very significant fluctuations relative to the market. the returns on MARKET and RepliCel Life are completely uncorrelated.
Auto-correlation | 1.00 |
Perfect predictability
RepliCel Life Sciences has perfect predictability. Overlapping area represents the amount of predictability between RepliCel Life time series from 7th of November 2025 to 22nd of December 2025 and 22nd of December 2025 to 5th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of RepliCel Life Sciences price movement. The serial correlation of 1.0 indicates that 100.0% of current RepliCel Life price fluctuation can be explain by its past prices.
| Correlation Coefficient | 1.0 | |
| Spearman Rank Test | 1.0 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, RepliCel Life Sciences reported net income of (4.07 Million). This is 101.19% lower than that of the Life Sciences Tools & Services sector and 105.82% lower than that of the Health Care industry. The net income for all United States stocks is 100.71% higher than that of the company.
RepliCel Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses RepliCel Life's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of RepliCel Life could also be used in its relative valuation, which is a method of valuing RepliCel Life by comparing valuation metrics of similar companies.RepliCel Life is currently under evaluation in net income category among its peers.
RepliCel Fundamentals
| Return On Asset | -1.65 | |||
| Operating Margin | (4.19) % | |||
| Current Valuation | 3.42 M | |||
| Shares Outstanding | 54.36 M | |||
| Shares Owned By Insiders | 68.42 % | |||
| Price To Earning | (1.00) X | |||
| Price To Sales | 8.35 X | |||
| Revenue | 353.74 K | |||
| Gross Profit | 353.74 K | |||
| EBITDA | (4.07 M) | |||
| Net Income | (4.07 M) | |||
| Cash And Equivalents | 228 K | |||
| Total Debt | 34.26 K | |||
| Current Ratio | 0.23 X | |||
| Book Value Per Share | (0.22) X | |||
| Cash Flow From Operations | (2.51 M) | |||
| Earnings Per Share | (0.09) X | |||
| Number Of Employees | 23 | |||
| Beta | 1.19 | |||
| Market Capitalization | 5.29 M | |||
| Total Asset | 591.79 K | |||
| Retained Earnings | (14.76 M) | |||
| Z Score | 39.0 | |||
| Net Asset | 591.79 K |
About RepliCel Life Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze RepliCel Life Sciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of RepliCel Life using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of RepliCel Life Sciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Other Information on Investing in RepliCel Pink Sheet
RepliCel Life financial ratios help investors to determine whether RepliCel Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in RepliCel with respect to the benefits of owning RepliCel Life security.